Inflammatory bowel diseases (IBD) affect mostly patients in their reproductive years. Therefore, the question of the safety of the medication used for IBD is frequently raised by female IBD patients. Active disease at the conception and during pregnancy has been related to adverse pregnancy outcomes. Thus, the active counselling of IBD patients about the importance of remission maintenance in this period is of great importance. Most drugs used for remission maintenance of IBD are safe for the use in the peri-conceptional period and during pregnancy and this should be emphasized during the counselling as well as in the multidisciplinary discussion with other specialists caring for the patient and the child.